Evidence map›Paper›PMID 41661348›Full record

ArticleAnnals of hematology2026

Long-term real-world thrombotic and clinical outcomes in polycythemia vera - a hospital-based i2b2 cohort study.

Natalie Neumark, Katarzyna Aleksandra Jalowiec, Andre Tichelli, Naomi Porret, Linet Njue, Kristina Vrotniakaite-Bajerciene, Raja Prince-Eladnani, Anne Angelillo-Scherrer, Sara C Meyer, Alicia Rovó

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Natalie NeumarkDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. nneumark@gmx.ch.
Katarzyna Aleksandra JalowiecDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Andre TichelliHematology, University Hospital of Basel, Basel, Switzerland.
Naomi PorretDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Linet NjueDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Kristina Vrotniakaite-BajercieneDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Raja Prince-EladnaniDepartment for BioMedical Research, University of Bern, Bern, Switzerland.
Anne Angelillo-ScherrerDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Sara C MeyerDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Alicia RovóDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Though the thrombotic risk in polycythemia vera (PV) is well known, long-term real-world data remain limited. This retrospective study at Bern University Hospital aimed to evaluate complications in PV patients, focusing on thrombotic events, associated risk factors, and disease outcomes. Among 727,731 screened adults, 107 PV patients were identified (median age 58 years, range 18–92; 51% male). Median follow-up was 115 months (range 1–353). Thrombotic events occurred in 56% of patients, including 58% arterial and 42% venous events. Arterial and venous thrombosis before or at diagnosis was documented in 9 (8.4%) and 36 (33.6%) patients, respectively, and in 13 (12.1%) during follow-up. Splanchnic thrombosis was associated with younger age and splenomegaly. Multivariate analysis showed an increased thrombotic risk linked to dyslipidemia (RR 2.573, 95% CI 1.058–6.257) and older age at diagnosis (> 60 years; RR 2.524, 95% CI 1.111–5.734). Risk of death increased with age (RR 1.052, 95% CI 1.009–1.097) and myelofibrosis transformation (RR 6.856, 95% CI 1.948–24.120). This long-term study confirms a high thrombotic burden in PV, especially arterial events. Splanchnic thrombosis typically presented early on in younger patients without recurrence. The high prevalence of cardiovascular risk factors highlights the critical importance of managing these risks to mitigate thrombotic complications in PV.

Indexed as

Polycythemia VeraThrombosisAdolescentAdultAgedAged, 80 and overCohort StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesRisk FactorsSwitzerlandYoung AdultMyelofibrosisMyeloproliferative neoplasmsPolycythemia veraSplanchnic thrombosisThrombotic complications

Identifiers

PMID41661348
PMCPMC12886313

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.